The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.
The drug major announced the launch of capecitabine tablets, a therapeutic equivalent generic version of Xeloda tablets, approved by the U.S. Food and Drug Administration (USFDA).
Capecitabine is an anti-cancer ( antineoplastic or cytotoxic ) chemotherapy drug. Dr. Reddy s capecitabine tablets, USP are available in 150mg and 500mg strengths in bottle count sizes of60 and 120, respectively.
The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health.
Dr. Reddy s Laboratories is an integrated pharmaceutical company. The scrip fell 1.79% to Rs 4612, extending decline for fourth day. The stock has declined by 4.4% in four sessions.
Synopsis
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA).
Agencies
In a regulatory filing, Dr Reddy s laboratories announced launch of Capecitabine tablets in the US.
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA).
In a regulatory filing, Dr Reddy s laboratories announced launch of Capecitabine tablets in the US.
Quoting IQVIA Health data, Dr Reddy s said the Xeloda brand and generic had US sales of approximately USD 90 million for the most recent 12 months ending in October 2020.